New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Tvardi Therapeutics, Inc.

TVRD

Healthcare Biotechnology

Tvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.

Revenue
+20.3%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

0.99 0.04 +4.21%

After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.

Market cap
$12.6M
P/E
n/m
Fwd P/E FY25e
n/m
Dividend yield
—
F-score
3/9
ROIC
0.00%
Net debt / EBITDA
1.1×
Payout ratio
—

Latest quarter Q1 FY2025 · quarter to March 2025

Revenue grew 20.3% on a year earlier, against −51.6% the quarter before.

Q1 FY2025 and the 7 quarters before it
Quarter Revenue, $m Growth, % Op. margin, % EPS, $
Q1 FY25 3 20.3 (169.5) (3.72)
Q4 FY24 1 (51.6) 1,137.5 (4.94)
Q3 FY24 3 (47.5) (222.1) (2.14)
Q2 FY24 1 (85.7) (724.6) (2.71)
Q1 FY24 2 (65.4) (1,389.5) (1.63)
Q4 FY23 3 (7.9) (1,085.5) (21.25)
Q3 FY23 5 (55.0) — —
Q2 FY23 7 (69.9) — —

Growth is on the same quarter a year earlier, and EPS is diluted. Negative figures in brackets.

Reports Mar 30, 2027 · Q4 FY26 · consensus EPS −$0.50

All quarters →

Capital & Financial Ratios $m

Size
Market Cap 13
Revenue ttm 8
Net income ttm (27)
Free cash flow ttm (27)
Net debt Q (22)
Valuation
P/E n/m
Forward P/E FY25e n/m
Price / sales 1.7
Forward P/S FY25e Powerpack
Price / FCF n/m
Price / book 0.8
Financial health
Current ratio Q 2.9 (at or above 1.5: strong)
Debt / equity Q n/m
Interest coverage Q —
Growth
Revenue growth FY25e +408.1% (at or above 10%: strong)
EPS growth FY25e +32.5% (at or above 15%: strong)
EPS growth FY26e +29.4% (at or above 15%: strong)
EPS growth, 5 yrs e +15.5% (at or above 15%: strong)
Insiders
Owned by insiders 20.5%

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates, FY25e the fiscal year ending in 2025; n/m is not meaningful, as a P/E on a loss. How we judge →

Compound annual growth

10y 5y 3y
Sales 8.43% (18.53%) (32.33%)
Cash Flow — — —
Earnings — — —
Book Value (14.89%) (39.05%) (49.09%)

Valuation

P/S against its own 10 years 2.15%
10-year low 10-year high
P/B against its own 10 years 4.05%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

1.8
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 0 1 13 20 135 23 42 21 7 — 8 +73.7% 42 47 — +13.2%
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 82.65 70.56 91.31 — 146.85 (8.7) pt
EBT (58) (58) (74) (107) 8 (88) (85) (119) (29) (18) (27) n/m
EBT margin, % (67,148.84) (6,402.74) (552.39) (539.02) 5.71 (384.06) (204.16) (565.21) (411.90) — (109.36) +66,736.9 pt
Net income (57) (58) (74) (106) 8 (88) (85) (119) (29) (18) (27) n/m
Per share, $
Per share, $ Revenue 0.11 1.05 13.52 16.79 102.61 16.35 28.09 13.94 2.77 — 2.94 +49.1%
Earnings (75.64) (66.99) (74.20) (89.68) 6.48 (62.67) (57.27) (78.88) (11.42) (2.46) (2.68) n/m
Cash flow (62.56) (63.29) (22.38) (92.20) (4.17) (42.67) (52.83) (61.23) (7.11) (3.17) (2.15) n/m
Capex (0.95) (0.02) (0.07) (0.02) (0.27) 0.02 (0.03) (1.58) (0.41) 0.00 0.00 n/m
Free cash flow (63.50) (63.31) (22.45) (92.21) (4.43) (42.65) (52.86) (62.81) (7.52) (3.17) (2.15) n/m
Book value 66.97 100.17 134.10 157.60 189.15 161.57 106.55 37.96 (35.40) 2.82 1.22 (29.7%)
Shares, m 1 1 1 1 1 1 1 2 3 7 10 +28.9%
Valuation, ×
Valuation, × P/E n/m n/m n/m n/m 168.02 n/m n/m n/m n/m — n/m 168.0
P/S 3,094.60 401.66 32.43 34.55 5.31 4.57 14.03 1.95 6.62 — 1.65 399.5
P/B 5.25 4.61 3.49 3.68 2.88 2.71 3.70 0.72 0.00 — 0.81 3.0
EV/Sales 2,408.83 308.81 21.18 26.93 4.00 3.35 10.55 (2.87) 6.43 — (1.29) 309.7
EV/FCF (4.31) (5.61) (13.62) (4.90) (92.50) (7.53) (5.61) 0.64 (2.14) — 0.36 (15.1)
Cash, $m
Cash, $m Operating cash flow (47) (55) (22) (109) (5) (60) (79) (92) (18) (23) (27) n/m
Capex (1) 0 0 0 0 0 0 (2) (1) — — +4.8%
Free cash flow (48) (55) (22) (109) (6) (60) (79) (94) (19) (23) (27) n/m
Balance, $m
Balance, $m Working capital 50 87 128 123 177 156 145 91 21 20 15 (9.4%)
Net debt (59) (93) (162) (152) (177) (165) (146) (101) (1) (31) (22) n/m
Shareholders’ equity 51 87 134 187 249 228 159 57 (91) 21 15 (9.4%)
Returns, %
Returns, % ROA (65.57) (72.28) (51.43) (50.20) 3.34 (34.13) (39.82) (76.94) (36.51) (54.15) (85.24) +11.4 pt
ROIC 0.00 0.00 0.00 (199.09) 4.69 (89.22) (421.75) 0.00 0.00 0.00 0.00 0.0 pt
ROE (73.54) (84.54) (67.16) (66.41) 3.86 (37.12) (44.25) (109.80) 172.69 51.90 (123.08) +125.4 pt
People
People Employees 34 37 55 67 80 84 106 55 10 12 — (10.9%)
Revenue/emp, $m 0.00 0.02 0.24 0.30 1.69 0.27 0.39 0.38 0.71 — — +102.4%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2024 · latest quarter Mar 2025 · fundamentals updated Nov 17, 2026

Tvardi Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BOLT Bolt Biotherapeutics, Inc. $13.2M — (loss-making) — (loss-making) −99.72% (below 0%: shrinking) n/m +68.66% (above 0%: growing) 100.00% (167,480.00%) Compare
ACTU Actuate Therapeutics, Inc. $12.9M — (loss-making) — — n/m +55.81% (above 0%: growing) — — Compare
GUTS Fractyl Health, Inc. $12.7M — (loss-making) — (loss-making) −57.14% (below 0%: shrinking) n/m +30.87% (above 0%: growing) 100.00% (840,333.33%) Compare
TVRD Tvardi Therapeutics, Inc. $12.6M — (loss-making) — (loss-making) +20.33% (above 0%: growing) n/m −49.89% (below 0%: shrinking) 100.00% (169.48%)
QNTM Quantum Biopharma Ltd. $12.6M — (loss-making) — (loss-making) — n/m −197.94% (below 0%: shrinking) 0.00% (79,749.48%) Compare
NEUP Neuphoria Therapeutics Inc. $12.6M — (loss-making) — (loss-making) — n/m +70.26% (above 0%: growing) 100.00% 43,872.18% Compare
DYAI Dyadic International Inc. $12.5M — (loss-making) — (loss-making) −61.44% (below 0%: shrinking) n/m +19.88% (above 0%: growing) 16.48% (403.56%) Compare
CASIF CASI Pharmaceuticals Inc. $12.4M — (loss-making) — (loss-making) −45.93% (below 0%: shrinking) n/m — 51.14% (147.67%) Compare
JSPR Jasper Therapeutics, Inc. $11.9M — (loss-making) — — n/m +67.81% (above 0%: growing) 0.09% (1,802.16%) Compare
Median of peers $12.6M — — −59.29% — +55.81% 51.14% (1,802.16%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed Apr 23, 2026

Ownership

Directors and executive officers, together 7.40%
Entities affiliated with Sporos 8.90%
Entities affiliated with Solas BioVentures 8.10%
Entities affiliated with Slate Path 7.50%
David J. Tweardy 7.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Tvardi Therapeutics, Inc. (TVRD) Latest News

What happened

  1. Other Tvardi Therapeutics received FDA pre-IND feedback supporting proposed Phase 2 development of TTI-109 in ulcerative colitis and potentially Crohn’s disease.
  2. Results Tvardi Therapeutics reported a third-quarter 2026 net loss of $6.1 million and said its $22.3 million in cash was expected to fund operations into Q3 2027.
18 more headlines
All TVRD news, as stories →
stockrow.com/TVRD · Data as of Nov 17, 2026 · For information only; not investment advice. · © 2026 stockrow.com